Drug intelligence / Profile preview

VRC-HIVDNA009-00-VP + VRC-ADJDNA004-IL2-VP

Development stage: Unknown
Lead developer: National Institute of Allergy and Infectious Diseases
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

VRC-HIVDNA009-00-VP + VRC-ADJDNA004-IL2-VP is a combination of an investigational multiclade HIV-1 DNA vaccine (VRC-HIVDNA009-00-VP) and a plasmid cytokine adjuvant encoding interleukin 2 fused to immunoglobulin (VRC-ADJDNA004-IL2-VP). The DNA vaccine consists of four plasmids encoding the HIV subtype B Gag–Pol–Nef fusion protein and modified envelope (Env) constructs from subtypes A, B, and C. The adjuvant component is designed to enhance immune responses by providing IL‑2 as an immunostimulatory signal. This combination aims to induce both humoral and cellular immune responses against multiple HIV clades for prevention or therapeutic intervention in HIV infection. Clinical studies have shown that the DNA vaccine is safe but only modestly immunogenic in humans[4][5][8].

Targets

IL-2R (Interleukin-2/interleukin-15 receptor complex)

Beyond the preview

Go deeper on VRC-HIVDNA009-00-VP + VRC-ADJDNA004-IL2-VP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRC-HIVDNA009-00-VP + VRC-ADJDNA004-IL2-VP.

Explore the full profile